Related Experiment Video
Updated: Apr 5, 2026
06:31
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation taVNS: Technique, Targeting, and Considerations
Published on: January 7, 2019
42.3K
Transcutaneous auricular vagus nerve stimulation for pediatric epilepsy: study protocol for a randomized controlled
Wei He1,2, Xiao-Yu Wang3, Li Zhou4
1Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, 100700, China. hazel7811@hotmail.com.
Trials
|August 22, 2015
Summary
This study investigates if transcutaneous auricular vagus nerve stimulation (ta-VNS) helps children with epilepsy. The trial will assess seizure frequency and quality of life improvements in pediatric epilepsy patients receiving ta-VNS.
Area of Science:
- Neurology
- Pediatric Epilepsy Research
- Non-invasive Neuromodulation
Background:
- Clinical observations suggest vagus nerve stimulation (VNS) may benefit pediatric epilepsy.
- Transcutaneous auricular vagus nerve stimulation (ta-VNS) offers a non-invasive VNS approach, increasing accessibility for pediatric epilepsy treatment.
- Limited clinical evidence currently exists for ta-VNS effectiveness in pediatric epilepsy.
Purpose of the Study:
- To evaluate the efficacy of transcutaneous auricular vagus nerve stimulation (ta-VNS) in improving pediatric epilepsy.
- To determine if ta-VNS treatment is beneficial for pediatric patients with epilepsy.
- To clarify the correlation between the anticonvulsive effect of ta-VNS and the improvement of sympathovagal imbalance.
Main Methods:
- A three-center, randomized, parallel, controlled trial involving pediatric patients aged 2 to 14 years with epilepsy.
- Random assignment to transcutaneous auricular vagus nerve stimulation (ta-VNS), transcutaneous auricular non-vagus nerve stimulation (tan-VNS), or a control group using Zelen's design.
- Outcome assessments including seizure frequency, EEG, heart rate variability (HRV), quality of life (QOL), and adverse events over 6 months, with long-term follow-up.
Main Results:
- Data collection on seizure frequency, EEG, HRV, QOL, and adverse events at baseline and 2, 4, and 6 months post-initiation.
- Follow-up assessments for seizure frequency and adverse events at 1 year and 1.5 years.
- Analysis of potential correlation between ta-VNS anticonvulsive effects and sympathovagal imbalance improvement.
Conclusions:
- The trial's results will elucidate the potential benefits of ta-VNS for pediatric epilepsy.
- Findings will clarify whether ta-VNS is an effective treatment for reducing seizures in children.
- The study aims to establish the relationship between ta-VNS efficacy and the normalization of sympathovagal imbalance.
